Search

Your search keyword '"Oo C"' showing total 80 results

Search Constraints

Start Over You searched for: Author "Oo C" Remove constraint Author: "Oo C"
80 results on '"Oo C"'

Search Results

1. Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial

2. Student Assessment Literacy: Indicators and Domains from the Literature

9. The effect of Isoprenyl Ether polymer molecular structure on cementitious composites

12. The properties of slag-silica fume ternary blended mortar with quarry dust

16. Pharmacokinetics and Dosage Recommendations for an Oseltamivir Oral Suspension for the Treatment of Influenza in Children.

17. Interactions between cimetidine, nitrofurantoin, and probenecid active transport into rat milk.

21. OI-B-3.

22. The effect of spent coffee ground (SCG) loading, matrix ratio and biological treatment of SCG on poly(hydroxybutyrate) (PHB)/poly(lactic acid) (PLA) polymer blend.

24. Physiologically-based pharmacokinetic modeling to inform dosing regimens and routes of administration of rifampicin and colistin combination against Acinetobacter baumannii.

25. The combination effect of meropenem/sulbactam/polymyxin-B on the pharmacodynamic parameters for mutant selection windows against carbapenem-resistant Acinetobacter baumannii .

26. Prediction of Tissue Exposures of Meropenem, Colistin, and Sulbactam in Pediatrics Using Physiologically Based Pharmacokinetic Modeling.

27. Metabolomic profiling of polymyxin-B in combination with meropenem and sulbactam against multi-drug resistant Acinetobacter baumannii .

28. Revamping the ever-changing landscape of drug development processes in the midst of COVID-19 pandemic.

31. New insights into the role and mechanism of c-Jun-N-terminal kinase signaling in the pathobiology of liver diseases.

36. QT Correction: Using an Observed Regression Factor Applicable to a Population Subset.

37. There is no better time than the present: nanotechnology as a disruptive innovation for drug development.

38. In vitro and in vivo metabolism of a novel chymase inhibitor, SUN13834, and the predictability of human metabolism using mice with humanized liver.

40. A feasibility study of differential delivery of levodopa ester and benserazide using site-specific intestinal loops in rats.

41. Reciprocating dialysis tube method: periodic tapping improved in vitro release/dissolution testing of suppositories.

43. Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years.

44. Pharmacokinetics and delivery of the anti-influenza prodrug oseltamivir to the small intestine and colon using site-specific delivery capsules.

45. Safety and pharmacology of oseltamivir in clinical use.

46. Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids.

48. Lack of pharmacokinetic interaction between the oral anti-influenza prodrug oseltamivir and aspirin.

49. Speechless after bone marrow transplantation: a rare complication of parainfluenza virus related group in an adult.

50. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies.

Catalog

Books, media, physical & digital resources